Juno Therapeutics, Inc.

Juno Therapeutics, Inc.

Juno Therapeutics, Inc.

Juno Therapeutics, a clinical-stage company, develops immunotherapies for thetreatment of cancer.
Founded
2013
Follow us
Alexa global traffic share
Acquired by
Celgene Corporation
1
24 Apr 2018
$9,000,000,000
GeekWire

Juno Therapeutics agrees to pay $24M to stockholders in suit over disclosure of patient deaths

$9,000,000,000
GeekWire

Longtime Juno Therapeutics CEO Hans Bishop leaves role after merger with Celgene

Strategy Health
GeekWire

Cell therapies are giving Seattle an edge in biotech, driving three acquisitions in under a month

Science Health Technology
GeekWire

Juno Therapeutics stock surges 50% after reports that Celgene is in talks to buy the company

Health
GeekWire

Juno Therapeutics’ giant new Seattle HQ is designed to destroy cancer

Health City life
GeekWire

Photos: Inside Juno Therapeutics’ new custom-built headquarters and cancer research labs

City life
GeekWire

Juno Therapeutics stock jumps 40% as rival Kite Pharma reaches deal to be acquired for $11.9B

Health
GeekWire

Juno Therapeutics posts mixed results, remains optimistic about treatment pipeline

Health Earnings
GeekWire

Juno Therapeutics beats earnings expectations, announces it will drop problem cancer drug

Health Earnings
GeekWire

Mayor Bill de Blasio wanted Juno Therapeutics to move to New York — here’s why it’s saying in Seattle

City life Health
GeekWire

Study of Juno Therapeutics cancer treatment shows high rates of remission, possible promise for other drugs

Health Science
GeekWire

Juno Therapeutics sued for securities fraud following patient death

Legal Health
GeekWire

Juno posts loss as it amps up R&D spending for cancer trials

Health Earnings
$10,000,000
GeekWire

The $10 million molecule: Juno Therapeutics’ acquisition of RedoxTherapies could improve cancer treatment

Health Science
Xconomy

FDA Lets Juno Jump Back Into T-Cell Trial, Minus One Chemo Drug

Health
GeekWire , Xconomy

FDA suspends Juno Therapeutics clinical trial for leukemia treatment after 2 patient deaths

Health
The Motley Fool

Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.

The Motley Fool

Why Juno Therapeutics Soared 10.5% Today

The Motley Fool

Better Buy: Juno Therapeutics vs. bluebird bio

The Motley Fool

8 Figures That Sum Up Juno Therapeutics' First Quarter

Health Earnings